Great Lakes Advisors LLC decreased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 19.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,508 shares of the company's stock after selling 3,220 shares during the quarter. Great Lakes Advisors LLC's holdings in Axsome Therapeutics were worth $1,143,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Meridian Wealth Management LLC lifted its holdings in Axsome Therapeutics by 0.7% during the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock worth $1,791,000 after buying an additional 150 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Axsome Therapeutics by 1.8% in the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock valued at $766,000 after purchasing an additional 164 shares during the period. KBC Group NV lifted its stake in shares of Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock valued at $113,000 after purchasing an additional 385 shares during the period. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $52,000. Finally, R Squared Ltd acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $64,000. Institutional investors and hedge funds own 81.49% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently weighed in on AXSM shares. Royal Bank of Canada increased their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Morgan Stanley increased their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Monday, March 3rd. Deutsche Bank Aktiengesellschaft began coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $167.36.
Check Out Our Latest Analysis on Axsome Therapeutics
Axsome Therapeutics Stock Up 0.9 %
AXSM stock traded up $1.14 during trading hours on Wednesday, reaching $125.90. 371,704 shares of the stock were exchanged, compared to its average volume of 644,005. The firm's 50-day moving average is $113.88 and its 200-day moving average is $99.47. The company has a market cap of $6.14 billion, a price-to-earnings ratio of -21.02 and a beta of 0.99. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Insider Activity
In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.40% of the stock is owned by corporate insiders.
Axsome Therapeutics Company Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
